Welcome to International Biotech Forum
1. Biocon
Established in the year 1978 Biocon, global biopharmaceutical enterprise is actively involved in the manufacturing and development of innovative technologies that includes large-scale chemical synthesis, microbial fermentation, mammalian cell culture, purification of protein & antibody and various aseptic formulations.
Chairman – Kiran Mazumdar-Shaw; Corporate Office – Bangalore, India | Sector – Private | Website – http://www.biocon.com
2. Serum Institute of India
Serum Institute of India Ltd. established in the year 1966 is the world’s largest producer of Measles and DTP group of vaccines. The company manufactures life-saving Biologicals including Anti-Snake Venom and Tetanus Antitoxin serum, DTP (Diphtheria, Tetanus and Pertussis) and MMR (Measles, Mumps and Rubella) group of vaccines at affordable prices.
Chairman – Cyrus S. Poonawalla; Location: Pune, India |
Sector – Private | Website – http://www.seruminstitute.com
3. Panacea Biotech Ltd
Panacea Biotec established in the year 1976, has strong R and D capabilities with a wide range of pipeline including:
Development various complex pharmaceutical generic compounds Technologies)
Development of New Chemical Entities (NCE)
Vaccines
Chairman – Soshil Kumar, Corporate Office – New Delhi, India |
| Business – Pharmaceutical, Biotechnology |
Sector – Private | Website – http://www.panacea-biotec.com
4. Novo Nordisk
Established in the year 1923, Novo Nordisk is the world’s leader in diabetes care, manufacturing broadest diabetes product that includes development of the most advanced products related to insulin delivery systems.
Chairman – Sten Scheibye, Corporate Office – Denmark,
Business -Sector –Pharmaceutical- Private | Website – http://www.novonordisk.co.in
5. GlaxoSmithKline Pharmaceuticals Ltd.
One of the earliest pharmaceutical companies in India is GSK India. It was established in the year 1924. The GSK India is an important group of manufacturing products of wide range of prescription medicines and vaccines in therapeutic areas such as dermatology, anti-infectives, diabetes, oncology, cardiovascular and respiratory diseases. The company also manufactures vaccines for prevention of hepatitis A and B, invasive diseases caused by H. influenzae, chickenpox, DPT, cervical cancer, rotavirus, Streptococcal pneumonia etc.
Chairman – Chris Gent; Corporate Office – London, United Kingdom
Business –Biotechnology and Pharmaceutical,
Sector – Private | Website – http://www.gsk-india.com
6. SIRO Clinpharm
Established in the year 1996 the company provides a wide range of services including Clinical Operations & Clinical Monitoring, Clinical Data management, medical and scientific writing, biostatistics and statistical programming, clinical trial supplies management, pharmacovigilance.
Chairman – Dr. Gautam Daftary; Corporate Office – Thane, India | | | Business – Drug Development; Sector – Private | Website – http://www.siroclinpharm.com
7. Novozymes, South Asia
Novozymes a biotech company established in 1925 strongly focus on production of novel enzymes. The company’s biosolution provides everything from the removal of trans fats in food to advancements in bioenergy sources.
Chairman – Københavns Lufthavne; Corporate Office – Bagsvaerd, Denmark; Novozymes South Asia Pvt. Ltd. Bangalore, India; Sector – Private | Website –www.novozymes.com
8. Zydus Cadila
Zydus Cadila, established in the year 1952, is a fully integrated, global healthcare company with complete healthcare solutions ranging from active pharmaceutical ingredients, formulations products related to animal health care to wellness products. The company is the only Indian pharma establishment that launched the world’s first drug NCE – Lipaglyn for treatment of diabetic dyslipidemia.
Chairman – Mr. Pankaj R. Patel, Corporate office-Ahmedabad, Sector- Private Website- http://www.zyduscadila.com
9. Indian Immunologicals
Indian Immunologicals Ltd. (IIL) was established in 1982 by The National Dairy Development Board (NDDB) with the focus to manufacture Foot and Mouth Disease (FMD) vaccine available to poor people at an affordable price. IIL provides a range of adult as well as child vaccines.
Chairman – Dr. Amrita Patel; Corporate Office – Hyderabad, India
Business-sector –Biotechnology-private; Website – http://www.indimmune.com
10. Wockhardt Ltd.
Established in the year 1960 Wockhardt Ltd. is an international manufacturer of biopharmaceutical formulations along with Active Pharmaceutical Ingredients (API).
An integrated multi-technology capability was developed by the company for manufacturing all types of dosage formulation that includes sterile injectables and lyophilised products.
Chairman – Habil Khorakiwala; Corporate Office – Mumbai, India;
Business – Sector Biotechnology and Pharmaceutics-private
Website – http://www.wockhardt.com
1 Amgen – USA
2 Genentech – USA
3 Serono – Switzerland
4 Biogen Idec – USA
5 Genzyme – USA
6 Chiron Corp. – USA
7 Gilead Sciences – USA
8 CSL – Australia
9 MedImmune – USA
10 Cephalon – USA
The biotechnology industry is comprised of hundreds of companies that fuse biology and technology to develop drugs and related products for the treatment of diseases and medical conditions. Today's biotechnology industry includes companies that make medical devices and diagnostics, as well as biofuels, biomaterials, pollution controls, and more. Among the largest companies in the industry are pharmaceutical companies like Vertex Pharmaceuticals Inc. (VRTX) and Gilead Sciences Inc. (GILD). Gilead's investigational compound named remdesivir is seen as having the potential to treat COVID-19.These companies generally focus on creating and testing new drug compounds for medical use, and must go through lengthy trial and approval processes for their products. This means investors often must wait for months or even years before knowing whether a potential drug therapy is usable or profitable.
In spite of the many challenges facing biotechnology companies, a number of enterprises have risen to the top of the list. Below, we take a look at the top 10 worldwide as measured by 12-month trailing (TTM) revenue. All figures are as of March 25, 2020 and all data is provided by YCharts.
Revenue (TTM): $18.3 billion
Net Income (TTM): $5.8 billion
Market Cap: $118.6 billion
1-Year Trailing Total Return: 0.5%
PE Ratio (TTM): 20.6
Novo Nordisk is a multinational biotech company headquartered in Denmark with production facilities in seven countries and affiliates or offices in 80 countries. The company's primary focus is diabetes care, hemophilia care, growth hormone therapy, and hormone replacement therapy. The company makes several drugs under various brand names including Levemir, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.
Revenue (TTM): $7.9 billion
Net Income (TTM): $2.1 billion
Market Cap: $49.5 billion
1-Year Trailing Total Return: 14.7%
PE Ratio (TTM): 24.4
Biopharmaceutical company Regeneron develops and markets drug treatments for patients with eye disease, cancer, cardiovascular diseases, allergic and inflammatory issues, and infectious diseases. Through its Regeneron Genetics Center, the company aims to conduct one of the largest gene sequencing operations worldwide.
Revenue (TTM): $5.0 billion
Net Income (TTM): $2.4 billion
Market Cap: $19.0 billion
1-Year Trailing Total Return: -34.1%
PE Ratio (TTM): 8.0
Alexion is a biopharmaceutical company that develops and markets immunoregulatory drugs for the treatment of cardiovascular and autoimmune diseases. Through its drug therapies, Alexion aims to provide patients with compounds that selectively target portions of the immune system which may allow diseases to proliferate.
Revenue (TTM): $4.2 billion
Net Income (TTM): $1.2 billion
Market Cap: $57.9 billion
1-Year Trailing Total Return: 22.9%
PE Ratio (TTM): 49.5
Biopharmaceutical company Vertex focuses on creating and marketing drug treatments for patients suffering from cancer, cystic fibrosis, autoimmune diseases, and neurological disorders, among others.
Revenue (TTM): $2.2 billion
Net Income (TTM): $0.5 billion
Market Cap: $5.4 billion
1-Year Trailing Total Return: -30.0%
PE Ratio (TTM): 10.5
Irish biopharmaceutical company Jazz Pharmaceuticals creates and commercializes drug products designed to address issues related to narcolepsy, psychiatry, pain management, and oncology. On March 25, the company announced FDA approval of its drug JZP-258 for the treatment of cataplexy or excessive daytime sleepiness.3
Revenue (TTM): $2.2 billion
Net Income (TTM): $0.5 billion
Market Cap: $14.6 billion
1-Year Trailing Total Return: -21.0%
PE Ratio (TTM): 32.9
Focusing on small molecule drugs for use in oncology primarily, Incyte is a biopharmaceutical company responsible for discovering, developing, and marketing drug therapies. The company is best known for its drug Jakafi, a treatment for myelofibrosis.
Revenue (TTM): $1.7 billion
Net Income (TTM): -$0.02 billion
Market Cap: $14.4 billion
1-Year Trailing Total Return: -9.3%
PE Ratio (TTM): N/A
A maker of therapeutic enzyme products, Biomarin Pharmaceutical develops drug treatments for lysosomal storage diseases as well as serious burns. The company also provides diagnostic and analytic services for carbohydrate biology applications.
Revenue (TTM): $1.4 billion
Net Income (TTM): -$0.1 billion
Market Cap: $3.9 billion
1-Year Trailing Total Return: -27.1%
PE Ratio (TTM): N/A
United Therapeutics primarily develops drug treatments for pulmonary hypertension, peripheral vascular disease, and other vascular conditions. Among the company's most popular medicines are Remodulin, Orenitram, Unituxin, and Tyvaso.
Revenue (TTM): $1.2 billion
Net Income (TTM): $-0.2 billion
Market Cap: $2.2 billion
1-Year Trailing Total Return: -58.6%
PE Ratio (TTM): N/A
Alkermes is an Irish biopharmaceutical company. This firm creates treatments for central nervous system disorders including depression, schizophrenia, and addiction. It also focuses on treatments for diabetes.
Revenue (TTM): $1.1 billion
Net Income (TTM): $0.3 billion
Market Cap: $6.2 billion
1-Year Trailing Total Return: -43.2%
PE Ratio (TTM): 21.7
Biotechnology company Ionis discovers and develops RNA-based therapeutic products. Its three primary, commercially-available medicines include WAYLIVRA, Spinraza, and Tegsedi. It also has drug treatments in various stages of development to treat Huntington's disease, ALS, and cardiovascular disease.